Neoantigen & Personalized Cancer Vaccines Market Likely to Surpass USD 5.5 Billion by 2035

Buy Now

Exploring novel growth opportunities on, “Neoantigen & Personalized Cancer Vaccines Market Size, Share & Trends Analysis Report by Vaccine Type (Peptide-based Neoantigen Vaccines, Self-amplifying RNA vaccines, DNA-based Neoantigen Vaccines, Dendritic Cell-based Vaccines, Viral Vector-based Vaccines, Whole Tumor Cell Vaccines, Combination Vaccines), Technology Platform, Cancer Type, Therapy Type, Development Phase, Route of Administration, Manufacturing Process, Antigen Selection Method, End-Users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A complete report exploring emerging market pathways in the neoantigen & personalized cancer vaccines market illuminates revenue acceleration levers highlighting how scalable product line extensions, targeted new-market entries, and strategic partnerships are poised to drive top-line growth, expand market share

Global Neoantigen & Personalized Cancer Vaccines Market Forecast 2035:

According to the report, the global neoantigen & personalized cancer vaccines market is likely to grow from USD 0.6 Billion in 2025 to USD 5.5 Billion in 2035 at a highest CAGR of 24.7% during the time period. The global neoantigen and personalized cancer vaccines market is advancing at a rapid pace as precision oncology and personalised immunotherapy are emerging as a key focus of cancer therapy. Advances in neoantigen prediction software, next-generation sequencing, AI-assisted immune-profiling and mRNA-based vaccine platforms are making it possible to deliver highly personalized therapies based on tumor mutation profile. These technologies enhance immune-activation, tumor-specific targeting, and prolong clinical responses.

Customized cancer-immunization protocols are transitioning beyond scientific idea to clinical practice, which is aided by breakthroughs in genomics, AI-driven antigen-discovery platforms, and automated vaccine-manufacturing systems. Digital bioinformatics tools and cloud-based immunology systems are reducing the development cost and increasing the design accuracy. For instance, in January 2025, the University of Liverpool collaborated with myNEO Therapeutics to facilitate a Phase 1 individualized cancer vaccine trial of non-small cell lung cancer, showing a rapid transition to clinical use of personalized cancer-vaccine technology.

The rising use of precision medicine, increased investments in oncology research, facilitative regulatory measures on personalized therapies, and the need to develop next-generation immunotherapies have further contributed to market growth. Improved clinical performance, quality of life, and increased international collaboration in academia, biotech and pharmaceutical industries further position the neoantigen and personalized cancer vaccines market in the long-term growth and potential therapeutic breakthrough.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Neoantigen & Personalized Cancer Vaccines Market”

The increased use of precision immunotherapy is driving the need of neoantigen and personalized cancer vaccines. Neoantigen prediction using AIs, next-gen sequencing, and mRNA platforms are allowing the use of highly targeted immune activation that can be more stable clinically. For instance, In March 2025, scientists at the Icahn School of Medicine at Mount Sinai announced that a personalized neoantigen vaccine displayed strong T-cell responses in a Phase 1 study of advanced cancers, adding to the therapeutic promise of personalized cancer-vaccination strategies. The momentum in the global market is propelled by the increasing programs in oncology and the growing investments in the personalized immunotherapy pipelines.

The neoantigen and personalized cancer vaccines market is still challenged by high development and manufacturing costs. Individual sequencing, complicated vaccine manufacturing, and cold-chain logistics drive up total costs, restricting access in cost effective areas. The changing regulatory directions and the necessity of the high-level diagnostic and research facilities also hinder adoption, especially in emerging markets.

Increased commercialization opportunities are being increased by expansion of decentralized production, automated bioinformatics and modular clinical trials. New opportunities are being generated by growing investments, biotech-academic collaborations and incorporation of combination therapies. Early-stage immunization and minimal-residual-disease management are also in favor of long-term development of personalized cancer vaccines.

Expansion of Global Neoantigen & Personalized Cancer Vaccines Market

“Broadening Product Pipeline with Next-Generation Personalized Cancer Immunotherapies”

The neoantigen and personalized cancer vaccines market is growing with manufacturers improving their product pipelines with new, advanced, patient-specific immunotherapies that target different cancer types. Firms are combining neoantigen prediction with AI, mRNA, and custom vaccine regimens to enhance immune targeting, increase treatment response, and minimize adverse reactions. The reduction in emphasis on inpatient immunization initiatives, the use of combinations of checkpoint inhibitors, and minimal-residual-disease management are all incorporated in the move to adopt these programs within hospitals, cancer centers, and specialized oncology clinics.
Market presence is being enhanced by strategic partnerships and technological advancement to enable global expansion support. The industry participants are making investments in automated vaccine production, high-throughput sequencing, and digital bioinformatics to expand production and satisfy the upward demand. Partnerships with research centers, biotech companies and clinical systems are broadening market coverage, enhancing patient access, and enabling integration of personalized immunotherapies into normal oncology treatment around the globe.

Regional Analysis of Global Neoantigen & Personalized Cancer Vaccines Market

The neoantigen and personalized cancer vaccines market is dominated by North America with its advanced oncology infrastructure, extensive use of personalized immunotherapies, and impressive concentration on precision cancer treatment. Established hospitals and cancer centers are also adopting the use of neoantigen-based vaccines together with the traditional treatment to enhance the immune targeting, clinical response, and survival of a patient. An advanced regulatory system, ecosystem of R&D, and effective ventures among biotech companies and educational centers in addition to the rising integration of AI-powered neoantigen prediction and high-throughput sequencing systems also support regional leadership.
The Asia-Pacific is becoming the most rapidly developing region due to the accelerated modernization of healthcare, the rise of cancer rates, and the growing interest in investing in precision oncology. The adoption is speeding up due to expansion of biotech manufacturing facilities, upgrading of hospital infrastructures in China, India, Japan, and South Korea, and government efforts which are favourable towards the development of immunotherapy. Collaborations in strategic partnerships, transfer of technology, and clinical trials are making the region a prime growth center of personalized cancer vaccines in the world.

Prominent players operating in the global neoantigen & personalized cancer vaccines market are Advaxis, Inc., Agenus Inc., Bavarian Nordic A/S, BioNTech SE, Bristol Myers Squibb Company, CureVac N.V., Genocea Biosciences, Inc., Gradalis, Inc., Gritstone bio, Inc., Immunocore Holdings plc, Lytix Biopharma, Merck & Co., Inc., Moderna, Inc., Nektar Therapeutics, Nouscom AG, Novartis AG, OSE Immunotherapeutics, Personalis, Inc., Pfizer Inc., Repertoire Immune Medicines, Transgene SA, Vaccibody AS, Other Key Players.

The global Neoantigen & Personalized Cancer Vaccines market has been segmented as follows:

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, By Vaccine Type

Peptide-based Neoantigen Vaccines
- RNA-based Neoantigen Vaccines
- mRNA vaccines
Self-amplifying RNA vaccines
DNA-based Neoantigen Vaccines
Dendritic Cell-based Vaccines
Viral Vector-based Vaccines
Whole Tumor Cell Vaccines
Combination Vaccines

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, By Technology Platform

Next-Generation Sequencing (NGS)
Exome Sequencing
Whole Genome Sequencing
Transcriptome Analysis
HLA Typing Technologies
Epitope Prediction Algorithms
Bioinformatics & AI-driven Prediction
Mass Spectrometry-based Identification

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, By Cancer Type

Melanoma
Non-Small Cell Lung Cancer (NSCLC)
Bladder Cancer
Colorectal Cancer
Breast Cancer
Glioblastoma
Pancreatic Cancer
Prostate Cancer
Ovarian Cancer
Head and Neck Cancer
Renal Cell Carcinoma
Other Solid Tumors

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, By Therapy Type

Monotherapy
Combination Therapy

Neoantigen vaccine + Checkpoint inhibitors
Neoantigen vaccine + Chemotherapy
Neoantigen vaccine + Targeted therapy
Neoantigen vaccine + Radiotherapy

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, By Development Phase

Preclinical Stage
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Approved/Commercialized

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, By Route of Administration

Subcutaneous
Intramuscular
Intradermal
Intravenous
Intranodal

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, By Manufacturing Process

In-house Manufacturing
Contract Manufacturing Organization (CMO)

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, By Antigen Selection Method

Mutation-derived Neoantigens
Tumor-associated Antigens (TAA)
Tumor-specific Antigens (TSA)
Viral Antigens
Overexpressed Self-antigens

Neoantigen & Personalized Cancer Vaccines Market, By End-Users

Hospitals & Cancer Centers
Specialty Clinics & Oncology Practices
Research & Academic Institutions
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Diagnostic Laboratories
Government & Public Health Organizations

Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Global Neoantigen & Personalized Cancer Vaccines Market Outlook
  - 2.1.1. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2025-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Global Healthcare Industry Overview, 2025
  - 3.1.1. Healthcare Industry Ecosystem Analysis
  - 3.1.2. Key Trends for Healthcare Industry
  - 3.1.3. Regional Distribution for Healthcare Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
  - 3.4.1. Import & Export Analysis, 2025
  - 3.4.2. Top Importing Countries
  - 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
  - 3.5.1. Manufacturer
    - 3.5.1.1. Based on the component & Raw material
  - 3.5.2. Supply Chain
  - 3.5.3. End Consumer
- 3.6. Raw Material Analysis
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Advancements in next-generation sequencing (NGS) and AI-based neoantigen identification enabling precise, patient-specific vaccine design
    - 4.1.1.2. Rising cancer incidence and demand for personalized immunotherapies with durable clinical responses
    - 4.1.1.3. Increasing R&D collaborations between biotech firms and academic institutions to accelerate clinical translation
  - 4.1.2. Restraints
    - 4.1.2.1. High manufacturing and development costs associated with individualized vaccine production
    - 4.1.2.2. Complex regulatory pathways and lengthy approval timelines for personalized biologics
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
  - 4.4.1. Antigen Discovery & Identification
  - 4.4.2. Preclinical & Clinical Development
  - 4.4.3. Manufacturing & Process Optimization
  - 4.4.4. Distribution & Cold-Chain Logistics
- 4.5. Cost Structure Analysis
  - 4.5.1. Parameter’s Share for Cost Associated
  - 4.5.2. COGP vs COGS
  - 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
  - 4.6.1. Regional Pricing Analysis
  - 4.6.2. Segmental Pricing Trends
  - 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. Global Neoantigen & Personalized Cancer Vaccines Market Demand
  - 4.9.1. Historical Market Size – Value (US$ Bn), 2020-2024
  - 4.9.2. Current and Future Market Size - Value (US$ Bn), 2025–2035
    - 4.9.2.1. Y-o-Y Growth Trends
    - 4.9.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Vaccine Type
- 6.1. Key Segment Analysis
- 6.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Vaccine Type, 2021-2035
  - 6.2.1. Peptide-based Neoantigen Vaccines
    - 6.2.1.1. RNA-based Neoantigen Vaccines
    - 6.2.1.2. mRNA vaccines
  - 6.2.2. Self-amplifying RNA vaccines
  - 6.2.3. DNA-based Neoantigen Vaccines
  - 6.2.4. Dendritic Cell-based Vaccines
  - 6.2.5. Viral Vector-based Vaccines
  - 6.2.6. Whole Tumor Cell Vaccines
  - 6.2.7. Combination Vaccines
7. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Technology Platform
- 7.1. Key Segment Analysis
- 7.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology Platform, 2021-2035
  - 7.2.1. Next-Generation Sequencing (NGS)
  - 7.2.2. Exome Sequencing
  - 7.2.3. Whole Genome Sequencing
  - 7.2.4. Transcriptome Analysis
  - 7.2.5. HLA Typing Technologies
  - 7.2.6. Epitope Prediction Algorithms
  - 7.2.7. Bioinformatics & AI-driven Prediction
  - 7.2.8. Mass Spectrometry-based Identification
8. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Cancer Type
- 8.1. Key Segment Analysis
- 8.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Cancer Type, 2021-2035
  - 8.2.1. Melanoma
  - 8.2.2. Non-Small Cell Lung Cancer (NSCLC)
  - 8.2.3. Bladder Cancer
  - 8.2.4. Colorectal Cancer
  - 8.2.5. Breast Cancer
  - 8.2.6. Glioblastoma
  - 8.2.7. Pancreatic Cancer
  - 8.2.8. Prostate Cancer
  - 8.2.9. Ovarian Cancer
  - 8.2.10. Head and Neck Cancer
  - 8.2.11. Renal Cell Carcinoma
  - 8.2.12. Other Solid Tumors
9. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Therapy Type
- 9.1. Key Segment Analysis
- 9.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapy Type, 2021-2035
  - 9.2.1. Monotherapy
  - 9.2.2. Combination Therapy
    - 9.2.2.1. Neoantigen vaccine + Checkpoint inhibitors
    - 9.2.2.2. Neoantigen vaccine + Chemotherapy
    - 9.2.2.3. Neoantigen vaccine + Targeted therapy
    - 9.2.2.4. Neoantigen vaccine + Radiotherapy
10. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Development Phase
- 10.1. Key Segment Analysis
- 10.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Development Phase, 2021-2035
  - 10.2.1. Preclinical Stage
  - 10.2.2. Phase I Clinical Trials
  - 10.2.3. Phase II Clinical Trials
  - 10.2.4. Phase III Clinical Trials
  - 10.2.5. Approved/Commercialized
11. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Route of Administration
- 11.1. Key Segment Analysis
- 11.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
  - 11.2.1. Subcutaneous
  - 11.2.2. Intramuscular
  - 11.2.3. Intradermal
  - 11.2.4. Intravenous
  - 11.2.5. Intranodal
12. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Manufacturing Process
- 12.1. Key Segment Analysis
- 12.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Manufacturing Process, 2021-2035
  - 12.2.1. In-house Manufacturing
  - 12.2.2. Contract Manufacturing Organization (CMO)
13. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by Antigen Selection Method
- 13.1. Key Segment Analysis
- 13.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Antigen Selection Method, 2021-2035
  - 13.2.1. Mutation-derived Neoantigens
  - 13.2.2. Tumor-associated Antigens (TAA)
  - 13.2.3. Tumor-specific Antigens (TSA)
  - 13.2.4. Viral Antigens
  - 13.2.5. Overexpressed Self-antigens
14. Global Neoantigen & Personalized Cancer Vaccines Market Analysis, by End-Users
- 14.1. Key Segment Analysis
- 14.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-Users, 2021-2035
  - 14.2.1. Hospitals & Cancer Centers
  - 14.2.2. Specialty Clinics & Oncology Practices
  - 14.2.3. Research & Academic Institutions
  - 14.2.4. Pharmaceutical & Biotechnology Companies
  - 14.2.5. Contract Research Organizations (CROs)
  - 14.2.6. Diagnostic Laboratories
  - 14.2.7. Government & Public Health Organizations
15. Global Neoantigen & Personalized Cancer Vaccines Market Analysis and Forecasts, by Region
- 15.1. Key Findings
- 15.2. Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
  - 15.2.1. North America
  - 15.2.2. Europe
  - 15.2.3. Asia Pacific
  - 15.2.4. Middle East
  - 15.2.5. Africa
  - 15.2.6. South America
16. North America Neoantigen & Personalized Cancer Vaccines Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. North America Neoantigen & Personalized Cancer Vaccines Market Size Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Vaccine Type
  - 16.3.2. Technology Platform
  - 16.3.3. Cancer Type
  - 16.3.4. Therapy Type
  - 16.3.5. Development Phase
  - 16.3.6. Route of Administration
  - 16.3.7. Manufacturing Process
  - 16.3.8. Antigen Selection Method
  - 16.3.9. End-Users
  - 16.3.10. Country
    - 16.3.10.1. USA
    - 16.3.10.2. Canada
    - 16.3.10.3. Mexico
- 16.4. USA Neoantigen & Personalized Cancer Vaccines Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Vaccine Type
  - 16.4.3. Technology Platform
  - 16.4.4. Cancer Type
  - 16.4.5. Therapy Type
  - 16.4.6. Development Phase
  - 16.4.7. Route of Administration
  - 16.4.8. Manufacturing Process
  - 16.4.9. Antigen Selection Method
  - 16.4.10. End-Users
- 16.5. Canada Neoantigen & Personalized Cancer Vaccines Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Vaccine Type
  - 16.5.3. Technology Platform
  - 16.5.4. Cancer Type
  - 16.5.5. Therapy Type
  - 16.5.6. Development Phase
  - 16.5.7. Route of Administration
  - 16.5.8. Manufacturing Process
  - 16.5.9. Antigen Selection Method
  - 16.5.10. End-Users
- 16.6. Mexico Neoantigen & Personalized Cancer Vaccines Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Vaccine Type
  - 16.6.3. Technology Platform
  - 16.6.4. Cancer Type
  - 16.6.5. Therapy Type
  - 16.6.6. Development Phase
  - 16.6.7. Route of Administration
  - 16.6.8. Manufacturing Process
  - 16.6.9. Antigen Selection Method
  - 16.6.10. End-Users
17. Europe Neoantigen & Personalized Cancer Vaccines Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Europe Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Vaccine Type
  - 17.3.2. Technology Platform
  - 17.3.3. Cancer Type
  - 17.3.4. Therapy Type
  - 17.3.5. Development Phase
  - 17.3.6. Route of Administration
  - 17.3.7. Manufacturing Process
  - 17.3.8. Antigen Selection Method
  - 17.3.9. End-Users
  - 17.3.10. Country
    - 17.3.10.1. Germany
    - 17.3.10.2. United Kingdom
    - 17.3.10.3. France
    - 17.3.10.4. Italy
    - 17.3.10.5. Spain
    - 17.3.10.6. Netherlands
    - 17.3.10.7. Nordic Countries
    - 17.3.10.8. Poland
    - 17.3.10.9. Russia & CIS
    - 17.3.10.10. Rest of Europe
- 17.4. Germany Neoantigen & Personalized Cancer Vaccines Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Vaccine Type
  - 17.4.3. Technology Platform
  - 17.4.4. Cancer Type
  - 17.4.5. Therapy Type
  - 17.4.6. Development Phase
  - 17.4.7. Route of Administration
  - 17.4.8. Manufacturing Process
  - 17.4.9. Antigen Selection Method
  - 17.4.10. End-Users
- 17.5. United Kingdom Neoantigen & Personalized Cancer Vaccines Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Vaccine Type
  - 17.5.3. Technology Platform
  - 17.5.4. Cancer Type
  - 17.5.5. Therapy Type
  - 17.5.6. Development Phase
  - 17.5.7. Route of Administration
  - 17.5.8. Manufacturing Process
  - 17.5.9. Antigen Selection Method
  - 17.5.10. End-Users
- 17.6. France Neoantigen & Personalized Cancer Vaccines Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Vaccine Type
  - 17.6.3. Technology Platform
  - 17.6.4. Cancer Type
  - 17.6.5. Therapy Type
  - 17.6.6. Development Phase
  - 17.6.7. Route of Administration
  - 17.6.8. Manufacturing Process
  - 17.6.9. Antigen Selection Method
  - 17.6.10. End-Users
- 17.7. Italy Neoantigen & Personalized Cancer Vaccines Market
  - 17.7.1. Country Segmental Analysis
  - 17.7.2. Vaccine Type
  - 17.7.3. Technology Platform
  - 17.7.4. Cancer Type
  - 17.7.5. Therapy Type
  - 17.7.6. Development Phase
  - 17.7.7. Route of Administration
  - 17.7.8. Manufacturing Process
  - 17.7.9. Antigen Selection Method
  - 17.7.10. End-Users
- 17.8. Spain Neoantigen & Personalized Cancer Vaccines Market
  - 17.8.1. Country Segmental Analysis
  - 17.8.2. Vaccine Type
  - 17.8.3. Technology Platform
  - 17.8.4. Cancer Type
  - 17.8.5. Therapy Type
  - 17.8.6. Development Phase
  - 17.8.7. Route of Administration
  - 17.8.8. Manufacturing Process
  - 17.8.9. Antigen Selection Method
  - 17.8.10. End-Users
- 17.9. Netherlands Neoantigen & Personalized Cancer Vaccines Market
  - 17.9.1. Country Segmental Analysis
  - 17.9.2. Vaccine Type
  - 17.9.3. Technology Platform
  - 17.9.4. Cancer Type
  - 17.9.5. Therapy Type
  - 17.9.6. Development Phase
  - 17.9.7. Route of Administration
  - 17.9.8. Manufacturing Process
  - 17.9.9. Antigen Selection Method
  - 17.9.10. End-Users
- 17.10. Nordic Countries Neoantigen & Personalized Cancer Vaccines Market
  - 17.10.1. Country Segmental Analysis
  - 17.10.2. Vaccine Type
  - 17.10.3. Technology Platform
  - 17.10.4. Cancer Type
  - 17.10.5. Therapy Type
  - 17.10.6. Development Phase
  - 17.10.7. Route of Administration
  - 17.10.8. Manufacturing Process
  - 17.10.9. Antigen Selection Method
  - 17.10.10. End-Users
- 17.11. Poland Neoantigen & Personalized Cancer Vaccines Market
  - 17.11.1. Country Segmental Analysis
  - 17.11.2. Vaccine Type
  - 17.11.3. Technology Platform
  - 17.11.4. Cancer Type
  - 17.11.5. Therapy Type
  - 17.11.6. Development Phase
  - 17.11.7. Route of Administration
  - 17.11.8. Manufacturing Process
  - 17.11.9. Antigen Selection Method
  - 17.11.10. End-Users
- 17.12. Russia & CIS Neoantigen & Personalized Cancer Vaccines Market
  - 17.12.1. Country Segmental Analysis
  - 17.12.2. Vaccine Type
  - 17.12.3. Technology Platform
  - 17.12.4. Cancer Type
  - 17.12.5. Therapy Type
  - 17.12.6. Development Phase
  - 17.12.7. Route of Administration
  - 17.12.8. Manufacturing Process
  - 17.12.9. Antigen Selection Method
  - 17.12.10. End-Users
- 17.13. Rest of Europe Neoantigen & Personalized Cancer Vaccines Market
  - 17.13.1. Country Segmental Analysis
  - 17.13.2. Vaccine Type
  - 17.13.3. Technology Platform
  - 17.13.4. Cancer Type
  - 17.13.5. Therapy Type
  - 17.13.6. Development Phase
  - 17.13.7. Route of Administration
  - 17.13.8. Manufacturing Process
  - 17.13.9. Antigen Selection Method
  - 17.13.10. End-Users
18. Asia Pacific Neoantigen & Personalized Cancer Vaccines Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. East Asia Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 18.3.1. Vaccine Type
  - 18.3.2. Technology Platform
  - 18.3.3. Cancer Type
  - 18.3.4. Therapy Type
  - 18.3.5. Development Phase
  - 18.3.6. Route of Administration
  - 18.3.7. Manufacturing Process
  - 18.3.8. Antigen Selection Method
  - 18.3.9. End-Users
  - 18.3.10. Country
    - 18.3.10.1. China
    - 18.3.10.2. India
    - 18.3.10.3. Japan
    - 18.3.10.4. South Korea
    - 18.3.10.5. Australia and New Zealand
    - 18.3.10.6. Indonesia
    - 18.3.10.7. Malaysia
    - 18.3.10.8. Thailand
    - 18.3.10.9. Vietnam
    - 18.3.10.10. Rest of Asia Pacific
- 18.4. China Neoantigen & Personalized Cancer Vaccines Market
  - 18.4.1. Country Segmental Analysis
  - 18.4.2. Vaccine Type
  - 18.4.3. Technology Platform
  - 18.4.4. Cancer Type
  - 18.4.5. Therapy Type
  - 18.4.6. Development Phase
  - 18.4.7. Route of Administration
  - 18.4.8. Manufacturing Process
  - 18.4.9. Antigen Selection Method
  - 18.4.10. End-Users
- 18.5. India Neoantigen & Personalized Cancer Vaccines Market
  - 18.5.1. Country Segmental Analysis
  - 18.5.2. Vaccine Type
  - 18.5.3. Technology Platform
  - 18.5.4. Cancer Type
  - 18.5.5. Therapy Type
  - 18.5.6. Development Phase
  - 18.5.7. Route of Administration
  - 18.5.8. Manufacturing Process
  - 18.5.9. Antigen Selection Method
  - 18.5.10. End-Users
- 18.6. Japan Neoantigen & Personalized Cancer Vaccines Market
  - 18.6.1. Country Segmental Analysis
  - 18.6.2. Vaccine Type
  - 18.6.3. Technology Platform
  - 18.6.4. Cancer Type
  - 18.6.5. Therapy Type
  - 18.6.6. Development Phase
  - 18.6.7. Route of Administration
  - 18.6.8. Manufacturing Process
  - 18.6.9. Antigen Selection Method
  - 18.6.10. End-Users
- 18.7. South Korea Neoantigen & Personalized Cancer Vaccines Market
  - 18.7.1. Country Segmental Analysis
  - 18.7.2. Vaccine Type
  - 18.7.3. Technology Platform
  - 18.7.4. Cancer Type
  - 18.7.5. Therapy Type
  - 18.7.6. Development Phase
  - 18.7.7. Route of Administration
  - 18.7.8. Manufacturing Process
  - 18.7.9. Antigen Selection Method
  - 18.7.10. End-Users
- 18.8. Australia and New Zealand Neoantigen & Personalized Cancer Vaccines Market
  - 18.8.1. Country Segmental Analysis
  - 18.8.2. Vaccine Type
  - 18.8.3. Technology Platform
  - 18.8.4. Cancer Type
  - 18.8.5. Therapy Type
  - 18.8.6. Development Phase
  - 18.8.7. Route of Administration
  - 18.8.8. Manufacturing Process
  - 18.8.9. Antigen Selection Method
  - 18.8.10. End-Users
- 18.9. Indonesia Neoantigen & Personalized Cancer Vaccines Market
  - 18.9.1. Country Segmental Analysis
  - 18.9.2. Vaccine Type
  - 18.9.3. Technology Platform
  - 18.9.4. Cancer Type
  - 18.9.5. Therapy Type
  - 18.9.6. Development Phase
  - 18.9.7. Route of Administration
  - 18.9.8. Manufacturing Process
  - 18.9.9. Antigen Selection Method
  - 18.9.10. End-Users
- 18.10. Malaysia Neoantigen & Personalized Cancer Vaccines Market
  - 18.10.1. Country Segmental Analysis
  - 18.10.2. Vaccine Type
  - 18.10.3. Technology Platform
  - 18.10.4. Cancer Type
  - 18.10.5. Therapy Type
  - 18.10.6. Development Phase
  - 18.10.7. Route of Administration
  - 18.10.8. Manufacturing Process
  - 18.10.9. Antigen Selection Method
  - 18.10.10. End-Users
- 18.11. Thailand Neoantigen & Personalized Cancer Vaccines Market
  - 18.11.1. Country Segmental Analysis
  - 18.11.2. Vaccine Type
  - 18.11.3. Technology Platform
  - 18.11.4. Cancer Type
  - 18.11.5. Therapy Type
  - 18.11.6. Development Phase
  - 18.11.7. Route of Administration
  - 18.11.8. Manufacturing Process
  - 18.11.9. Antigen Selection Method
  - 18.11.10. End-Users
- 18.12. Vietnam Neoantigen & Personalized Cancer Vaccines Market
  - 18.12.1. Country Segmental Analysis
  - 18.12.2. Vaccine Type
  - 18.12.3. Technology Platform
  - 18.12.4. Cancer Type
  - 18.12.5. Therapy Type
  - 18.12.6. Development Phase
  - 18.12.7. Route of Administration
  - 18.12.8. Manufacturing Process
  - 18.12.9. Antigen Selection Method
  - 18.12.10. End-Users
- 18.13. Rest of Asia Pacific Neoantigen & Personalized Cancer Vaccines Market
  - 18.13.1. Country Segmental Analysis
  - 18.13.2. Vaccine Type
  - 18.13.3. Technology Platform
  - 18.13.4. Cancer Type
  - 18.13.5. Therapy Type
  - 18.13.6. Development Phase
  - 18.13.7. Route of Administration
  - 18.13.8. Manufacturing Process
  - 18.13.9. Antigen Selection Method
  - 18.13.10. End-Users
19. Middle East Neoantigen & Personalized Cancer Vaccines Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Middle East Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 19.3.1. Vaccine Type
  - 19.3.2. Technology Platform
  - 19.3.3. Cancer Type
  - 19.3.4. Therapy Type
  - 19.3.5. Development Phase
  - 19.3.6. Route of Administration
  - 19.3.7. Manufacturing Process
  - 19.3.8. Antigen Selection Method
  - 19.3.9. End-Users
  - 19.3.10. Country
    - 19.3.10.1. Turkey
    - 19.3.10.2. UAE
    - 19.3.10.3. Saudi Arabia
    - 19.3.10.4. Israel
    - 19.3.10.5. Rest of Middle East
- 19.4. Turkey Neoantigen & Personalized Cancer Vaccines Market
  - 19.4.1. Country Segmental Analysis
  - 19.4.2. Vaccine Type
  - 19.4.3. Technology Platform
  - 19.4.4. Cancer Type
  - 19.4.5. Therapy Type
  - 19.4.6. Development Phase
  - 19.4.7. Route of Administration
  - 19.4.8. Manufacturing Process
  - 19.4.9. Antigen Selection Method
  - 19.4.10. End-Users
- 19.5. UAE Neoantigen & Personalized Cancer Vaccines Market
  - 19.5.1. Country Segmental Analysis
  - 19.5.2. Vaccine Type
  - 19.5.3. Technology Platform
  - 19.5.4. Cancer Type
  - 19.5.5. Therapy Type
  - 19.5.6. Development Phase
  - 19.5.7. Route of Administration
  - 19.5.8. Manufacturing Process
  - 19.5.9. Antigen Selection Method
  - 19.5.10. End-Users
- 19.6. Saudi Arabia Neoantigen & Personalized Cancer Vaccines Market
  - 19.6.1. Country Segmental Analysis
  - 19.6.2. Vaccine Type
  - 19.6.3. Technology Platform
  - 19.6.4. Cancer Type
  - 19.6.5. Therapy Type
  - 19.6.6. Development Phase
  - 19.6.7. Route of Administration
  - 19.6.8. Manufacturing Process
  - 19.6.9. Antigen Selection Method
  - 19.6.10. End-Users
- 19.7. Israel Neoantigen & Personalized Cancer Vaccines Market
  - 19.7.1. Country Segmental Analysis
  - 19.7.2. Vaccine Type
  - 19.7.3. Technology Platform
  - 19.7.4. Cancer Type
  - 19.7.5. Therapy Type
  - 19.7.6. Development Phase
  - 19.7.7. Route of Administration
  - 19.7.8. Manufacturing Process
  - 19.7.9. Antigen Selection Method
  - 19.7.10. End-Users
- 19.8. Rest of Middle East Neoantigen & Personalized Cancer Vaccines Market
  - 19.8.1. Country Segmental Analysis
  - 19.8.2. Vaccine Type
  - 19.8.3. Technology Platform
  - 19.8.4. Cancer Type
  - 19.8.5. Therapy Type
  - 19.8.6. Development Phase
  - 19.8.7. Route of Administration
  - 19.8.8. Manufacturing Process
  - 19.8.9. Antigen Selection Method
  - 19.8.10. End-Users
20. Africa Neoantigen & Personalized Cancer Vaccines Market Analysis
- 20.1. Key Segment Analysis
- 20.2. Regional Snapshot
- 20.3. Africa Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 20.3.1. Vaccine Type
  - 20.3.2. Technology Platform
  - 20.3.3. Cancer Type
  - 20.3.4. Therapy Type
  - 20.3.5. Development Phase
  - 20.3.6. Route of Administration
  - 20.3.7. Manufacturing Process
  - 20.3.8. Antigen Selection Method
  - 20.3.9. End-Users
  - 20.3.10. Country
    - 20.3.10.1. South Africa
    - 20.3.10.2. Egypt
    - 20.3.10.3. Nigeria
    - 20.3.10.4. Algeria
    - 20.3.10.5. Rest of Africa
- 20.4. South Africa Neoantigen & Personalized Cancer Vaccines Market
  - 20.4.1. Country Segmental Analysis
  - 20.4.2. Vaccine Type
  - 20.4.3. Technology Platform
  - 20.4.4. Cancer Type
  - 20.4.5. Therapy Type
  - 20.4.6. Development Phase
  - 20.4.7. Route of Administration
  - 20.4.8. Manufacturing Process
  - 20.4.9. Antigen Selection Method
  - 20.4.10. End-Users
- 20.5. Egypt Neoantigen & Personalized Cancer Vaccines Market
  - 20.5.1. Country Segmental Analysis
  - 20.5.2. Vaccine Type
  - 20.5.3. Technology Platform
  - 20.5.4. Cancer Type
  - 20.5.5. Therapy Type
  - 20.5.6. Development Phase
  - 20.5.7. Route of Administration
  - 20.5.8. Manufacturing Process
  - 20.5.9. Antigen Selection Method
  - 20.5.10. End-Users
- 20.6. Nigeria Neoantigen & Personalized Cancer Vaccines Market
  - 20.6.1. Country Segmental Analysis
  - 20.6.2. Vaccine Type
  - 20.6.3. Technology Platform
  - 20.6.4. Cancer Type
  - 20.6.5. Therapy Type
  - 20.6.6. Development Phase
  - 20.6.7. Route of Administration
  - 20.6.8. Manufacturing Process
  - 20.6.9. Antigen Selection Method
  - 20.6.10. End-Users
- 20.7. Algeria Neoantigen & Personalized Cancer Vaccines Market
  - 20.7.1. Country Segmental Analysis
  - 20.7.2. Vaccine Type
  - 20.7.3. Technology Platform
  - 20.7.4. Cancer Type
  - 20.7.5. Therapy Type
  - 20.7.6. Development Phase
  - 20.7.7. Route of Administration
  - 20.7.8. Manufacturing Process
  - 20.7.9. Antigen Selection Method
  - 20.7.10. End-Users
- 20.8. Rest of Africa Neoantigen & Personalized Cancer Vaccines Market
  - 20.8.1. Country Segmental Analysis
  - 20.8.2. Vaccine Type
  - 20.8.3. Technology Platform
  - 20.8.4. Cancer Type
  - 20.8.5. Therapy Type
  - 20.8.6. Development Phase
  - 20.8.7. Route of Administration
  - 20.8.8. Manufacturing Process
  - 20.8.9. Antigen Selection Method
  - 20.8.10. End-Users
21. South America Neoantigen & Personalized Cancer Vaccines Market Analysis
- 21.1. Key Segment Analysis
- 21.2. Regional Snapshot
- 21.3. Central and South Africa Neoantigen & Personalized Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 21.3.1. Vaccine Type
  - 21.3.2. Technology Platform
  - 21.3.3. Cancer Type
  - 21.3.4. Therapy Type
  - 21.3.5. Development Phase
  - 21.3.6. Route of Administration
  - 21.3.7. Manufacturing Process
  - 21.3.8. Antigen Selection Method
  - 21.3.9. End-Users
  - 21.3.10. Country
    - 21.3.10.1. Brazil
    - 21.3.10.2. Argentina
    - 21.3.10.3. Rest of South America
- 21.4. Brazil Neoantigen & Personalized Cancer Vaccines Market
  - 21.4.1. Country Segmental Analysis
  - 21.4.2. Vaccine Type
  - 21.4.3. Technology Platform
  - 21.4.4. Cancer Type
  - 21.4.5. Therapy Type
  - 21.4.6. Development Phase
  - 21.4.7. Route of Administration
  - 21.4.8. Manufacturing Process
  - 21.4.9. Antigen Selection Method
  - 21.4.10. End-Users
- 21.5. Argentina Neoantigen & Personalized Cancer Vaccines Market
  - 21.5.1. Country Segmental Analysis
  - 21.5.2. Vaccine Type
  - 21.5.3. Technology Platform
  - 21.5.4. Cancer Type
  - 21.5.5. Therapy Type
  - 21.5.6. Development Phase
  - 21.5.7. Route of Administration
  - 21.5.8. Manufacturing Process
  - 21.5.9. Antigen Selection Method
  - 21.5.10. End-Users
- 21.6. Rest of South America Neoantigen & Personalized Cancer Vaccines Market
  - 21.6.1. Country Segmental Analysis
  - 21.6.2. Vaccine Type
  - 21.6.3. Technology Platform
  - 21.6.4. Cancer Type
  - 21.6.5. Therapy Type
  - 21.6.6. Development Phase
  - 21.6.7. Route of Administration
  - 21.6.8. Manufacturing Process
  - 21.6.9. Antigen Selection Method
  - 21.6.10. End-Users
22. Key Players/ Company Profile
- 22.1. Advaxis, Inc.
  - 22.1.1. Company Details/ Overview
  - 22.1.2. Company Financials
  - 22.1.3. Key Customers and Competitors
  - 22.1.4. Business/ Industry Portfolio
  - 22.1.5. Product Portfolio/ Specification Details
  - 22.1.6. Pricing Data
  - 22.1.7. Strategic Overview
  - 22.1.8. Recent Developments
- 22.2. Agenus Inc.
- 22.3. Bavarian Nordic A/S
- 22.4. BioNTech SE
- 22.5. Bristol Myers Squibb Company
- 22.6. CureVac N.V.
- 22.7. Genocea Biosciences, Inc.
- 22.8. Gradalis, Inc.
- 22.9. Gritstone bio, Inc.
- 22.10. Immunocore Holdings plc
- 22.11. Lytix Biopharma
- 22.12. Merck & Co., Inc.
- 22.13. Moderna, Inc.
- 22.14. Nektar Therapeutics
- 22.15. Nouscom AG
- 22.16. Novartis AG
- 22.17. OSE Immunotherapeutics
- 22.18. Personalis, Inc.
- 22.19. Pfizer Inc.
- 22.20. Repertoire Immune Medicines
- 22.21. Transgene SA
- 22.22. Vaccibody AS
- 22.23. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation